Top

Published in:

01-01-2011 | Original Article

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Authors: Roland Penzel, Christine Sers, Yuan Chen, Ulrich Lehmann-Mühlenhoff, Sabine Merkelbach-Bruse, Andreas Jung, Thomas Kirchner, Reinhard Büttner, Hans H. Kreipe, Iver Petersen, Manfred Dietel, Peter Schirmacher

Published in: Virchows Archiv | Issue 1/2011

Abstract

EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed.

Available only for authorised users

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMed

Marchetti A, Felicioni L, Buttitta F, Tsao MS, Kamel-Reid S, Shepherd FA (2006) Assessing EGFR mutations. N Engl J Med 354:526–528CrossRefPubMed

Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–1681CrossRefPubMed

Somatic Mutations in Epidermal Growth Factor Receptor DataBase (2008) Department of Molecular Pathology and Translational Oncology at Metropolitan Hospital, Athens, Greece. www.somaticmutations-egfr.info/index.html

Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431CrossRefPubMed

Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967CrossRefPubMed

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267–5273CrossRefPubMed

Title: EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
Authors: Roland Penzel
Christine Sers
Yuan Chen
Ulrich Lehmann-Mühlenhoff
Sabine Merkelbach-Bruse
Andreas Jung
Thomas Kirchner
Reinhard Büttner
Hans H. Kreipe
Iver Petersen
Manfred Dietel
Peter Schirmacher
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 1/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-010-1000-y

At a glance: The STEP trials

Springer Medicine

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Use of alginate gel in the pathological work-up of the endoscopically resected mucosal lesions

Immunophenotypic predictive profiling of BRCA1-associated breast cancer

Philadelphia: cradle of American pathology

Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations

Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis

Chromosome 3p alterations in pancreatic endocrine neoplasia